Abstract
Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702
Journal of clinical oncology, Vol.44(2_suppl), pp.163-163
01/10/2026
DOI: 10.1200/JCO.2026.44.2_suppl.163
Abstract
163 Background: Being physically inactive is an independent predictor of poor outcomes in patients with stage III colon cancer. Whether physical activity can mitigate the oncologic risk of postoperative MRD is unknown. Methods: We concluded a post hoc analysis of a phase III trial evaluating celecoxib vs. placebo and 3 vs. 6 months of adjuvant chemotherapy in patients with resected stage III colon cancer. Self-reported physical activity was assessed in standardized measures of metabolic equivalent hours per week (MET-h/wk) at 2 timepoints: 1) midway through and 2) 6 months after completing adjuvant chemotherapy, modeled as a time-weighted average. MRD was determined via a clinically validated, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera, Natera, Inc.). Disease-free survival (DFS) and overall survival (OS) were estimated using flexible parametric survival models. Results: Among 763 patients (median follow-up 6.0 years), 24% were highly active (≥18 MET-h/wk) and 32% were inactive (<3 MET-h/wk); 18% were ctDNA positive. Adjusting for covariates, DFS improved in patients who were ctDNA negative and moderately active (Ref: inactive; 3-17.9 MET-h/wk; HR=0.62, 95% CI [0.40-0.97]) or highly active (HR = 0.53 [0.30-0.94]). No benefit was seen among patients who were ctDNA positive (Ref: inactive; moderately active: HR = 1.20 [0.75-1.92]; highly active: HR=0.83 [0.45-1.54]). The interaction was not significant (Pint=0.269). Physical activity did not impact OS regardless of ctDNA status. The interaction of physical activity and adjuvant celecoxib use is shown in Table. Conclusions: Among patients who were ctDNA negative, physical activity was associated with improved DFS, and may demonstrate increased survival benefit alongside adjuvant celecoxib. The additive effects of both interventions were inconclusive among those who were ctDNA positive. Support: U10CA180821, U10CA180882, U24CA196171; https://acknowledgments.alliancefound.org; Natera, Pfizer; NCT01150045. Disease-free survival by physical activity level and celecoxib use, stratified by ctDNA status. 3-yr event # at risk Adjusted HR (95% CI) P-value Pint ctDNA Negative 0.258 Inactive + placebo 23 182 Ref Active + placebo 17 132 0.74 (0.43-1.28) 0.283 Inactive + celecoxib 23 167 0.92 (0.57-1.48) 0.720 Active + celecoxib 10 146 0.40 (0.22-0.79) 0.007 ctDNA Positive 0.221 Inactive + placebo 26 33 Ref Active + placebo 15 20 0.96 (0.50-1.84) 0.903 Inactive + celecoxib 34 54 0.62 (0.37-1.05) 0.076 Active + celecoxib 14 29 0.34 (0.18-0.64) 0.001 ctDNA, circulating tumor DNA; HR, hazard ratio; CI, confidence interval. Active = ≥9 MET-h/week, inactive = <9 MET-h/week. Celecoxib use defined by assignment in CALGB/SWOG 80702. Models adjusted by T and N stage, age, sex, race, assigned cycles of fluorouracil, leucovorin, and oxaliplatin, KRAS and BRAF status, BMI, and Western diet.
Details
- Title: Subtitle
- Physical activity and molecular residual disease (MRD) in stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702
- Creators
- George Q. Zhang - Brigham and Women's HospitalChao Ma - Dana-Farber Cancer InstituteQian Shi - Mayo ClinicJonathan Andrew Nowak - Brigham and Women's HospitalLevi D. Pederson - Mayo ClinicTyler Twombly - Brigham and Women's HospitalJuha P. Väyrynen - University of OuluMelissa M. Zhao - Brigham and Women's HospitalYasutoshi Takashima - Dana-Farber Cancer InstituteArdaman Shergill - University of ChicagoPankaj Kumar - Illinois CancerCareFelix Couture - Hôtel-Dieu de QuébecJ. Philip Kuebler - Columbus Community Clinical Oncology ProgramSmitha S. Krishnamurthi - Cleveland ClinicBenjamin R. Tan - Washington University in St. LouisShuji Ogino - Brigham and Women's HospitalJustin Brown - Adventist University of Health SciencesAdham A. Jurdi - NateraAnthony F. ShieldsJeffrey A. Meyerhardt - Dana-Farber Cancer Institute
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.44(2_suppl), pp.163-163
- DOI
- 10.1200/JCO.2026.44.2_suppl.163
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 01/10/2026
- Academic Unit
- Biostatistics
- Record Identifier
- 9985123736702771
Metrics
1 Record Views